Real‐world data on the efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis
Real‐world data on the efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Real‐world data on the efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis have?
Real‐world data on the efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis has 75 citations in the OpenAlex counts ScholarIQ stores.
When was Real‐world data on the efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis published?
Real‐world data on the efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis has 2018 year in the ScholarIQ index.
What is the open-access status of Real‐world data on the efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis?
Real‐world data on the efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis has closed oa status in the ScholarIQ index.
What is the DOI of Real‐world data on the efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis?
The DOI for Real‐world data on the efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis is on the source record.
What is the PMID of Real‐world data on the efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis?
The PMID for Real‐world data on the efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis is on the source record.
What is the OpenAlex record for Real‐world data on the efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis?
The OpenAlex for Real‐world data on the efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis is on the source record.